Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

BACKGROUND: Therapeutic strategies with immune checkpoint inhibitors (ICIs) counteract the immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD-L1). ICI treatment has emerged in first- and second-line therapy of non–small cell lung cancer (NSCLC). As immunotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Gernot, Stollenwerk, Hannah Karolina, Klerings, Irma, Pecherstorfer, Martin, Gartlehner, Gerald, Singer, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458604/
https://www.ncbi.nlm.nih.gov/pubmed/32923134
http://dx.doi.org/10.1080/2162402X.2020.1774314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458604/
https://www.ncbi.nlm.nih.gov/pubmed/32923134
http://dx.doi.org/10.1080/2162402X.2020.1774314

Ejemplares similares